SUMMARY
High incidence of respiratory viral infection along with result-ing LRTI and mortality continues to be a major clinical problem in patients with HM and HCT recipients. Lack of directed an-tiviral therapy and vaccination against most of these viruses makes the matters worse. In the absence of randomized clinical trials, it is crucial to identify highrisk patients within this pa-tient population who may benefit the most from preemptive antiviral therapy. Novel antiviral agents and potent vaccines are needed to prevent outbreaks and epidemics in the commu-nity. In addition, data are needed to describe the epidemiology, risk factors, and outcome characteristics of respiratory viruses that are now routinely detected by multiplex PCR assays, such as coronaviruses and human rhinoviruses. Infection control and awareness among healthcare workers and patients alike remain the mainstays for reducing the burden of these viral infections.
